They have a portfolio of more than 15 companies, and invest only in New Zealand healthcare companies.
This is Cure Kids Ventures (CKV), founded and owned by Cure Kids Foundation, and New Zealand’s predominant seed and early stage healthcare investment fund.
Cure Kids Foundation has funded nearly $40 million in health research over more than 40 years. This research funding has enabled vast improvements in children’s health – extending, improving and saving the lives of millions of kids, both in New Zealand and around the world.
“Cure Kids Foundation invests in research that benefits child health and through CKV, invests in the commercialisation of innovations with the potential to benefit child health,” says Maxine Simmons, Executive Director of CKV.
With its New Zealand investment focus, they have targeted investments in medical devices, medications, diagnostics, health information technology and healthcare delivery systems. Their team has global experience in the biotech, healthcare and medical devices industry, and skills ranging from early stage company development and intellectual property through to commercialisation, global expansion, science, finance, legal, and mergers and acquisitions.
Caroline Quay, Chief Investment Officer of CKV says their most significant initiative to date is establishment of the CKV Co-Fund in 2017, enabling eligible investors interested in emerging healthcare companies to invest alongside CKV .
“This was the first time CKV launched a separate healthcare specific seed and early stage investment fund in New Zealand. We raised $2 million for the CKV Co-Fund. Together with CKV’s fund, we have $6 million to invest in emerging healthcare companies in New Zealand in the next few years”.
The CKV Co-Fund meets some key challenges around seed and early stage healthcare investment including the lack of sector specific expertise to assess healthcare investments.
“The CKV Co-Fund addresses these challenges by giving investors access to our healthcare specific expertise, our growing pipeline of opportunities and a diversified portfolio of healthcare investments,” says Ms Quay
CKV has also been working on solutions to address some of the problems affecting healthcare startup companies, specifically access to capital, sector specific expertise and market channels. “Our strategies include working on engaging with potential co-investment partners locally and internationally and exploring possible partnership/collaboration opportunities for portfolio companies with corporates, the big international pharmaceutical and medical device companies.“
“We are impressed with the quality and quantity of world-class scientific research and innovation we have seen in the last 10 years and think New Zealand is well placed to become an important part of the global healthcare sector with its scientific excellence and ease of doing business.”
CKV believes that an increasing level of capital investment, sector specific commercialisation expertise and a focus on global markets will greatly accelerate the progress of New Zealand’s emerging healthcare companies.
By Prue Scott